Affron Saffron has made a major achievement by getting the first-ever approval for stress relief from South Korea’s Ministry of Food and Drug Safety (MFDS). This approval highlights the growing use of standardized saffron extracts in healthcare products in Asia, especially in South Korea, where the regulations for health claims are strict.
Affron is a saffron extract that has been shown to aid in lowering stress in clinical studies. The MFDS approved it based on strong evidence showing improvements in stress levels, cortisol, and mood. This positions Affron as a major ingredient for use in stress relief products in the pharmaceutical as well as research industries.
South Korea’s MFDS requires high-quality evidence to support health claims, and the approval was based on Affron’s standardized formula, making sure the product’s effectiveness and stability. This opens up opportunities for manufacturers in South Korea to use Affron in their stress-relief products, fastening up their market entry.
For pharmaceutical companies across Asia, this approval could make it easier to introduce Affron-based products in other markets. It also helps sourcing and compliance teams find reliable, natural ingredients with proven benefits.
This approval could lead to more partnerships and manufacturing opportunities for Affron in Asia, making it a strong alternative to synthetic ingredients in stress-relief medications. It could also lead to new innovations in drug development, particularly for mental wellness.
